- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
First-time generic approvals
Paroxetine oral suspension 10 mg/5 mL equiv base (equiv to Paxil oral suspension 10 mg/5 mL equiv base)
Paroxetine oral suspension 10 mg/5 mL equiv base (equiv to Paxil oral suspension 10 mg/5 mL equiv base)
APOTEX
Oxandrolone tablets, 2.5 mg (equiv to Oxandrin tablets, 2.5 mg)
Oxandrolone tablets, 10 mg (equiv to Oxandrin tablets, 10 mg)
SANDOZ
Ondansetron injection single (4 mg/2 mL) and multidose (40 mg/20 mL) vials (equiv to Zofran injection)
TEVA
Ondansetron injection premixed 32 mg/50 mL in 5% dextrose (equiv to Zofran injection premixed)
SICOR
Sulfacetamide topical suspension USP 10% (equiv to Klaron lotion)
FOUGERA
Trandolapril tablets, 1, 2, and 4 mg (equiv to Mavik tablets, 1, 2, and 4 mg)
TEVA
Employers Face Barriers With Adopting Biosimilars
March 1st 2022Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.
